See, e.g., KolataG.B., Liver Transplants Endorsed, Science 221(4606): 221 (July 8, 1983) (example of the usual consensus panel process at the National Institutes of Health).
2.
See WehrE., National Health Policy Sought for Organ Transplant Surgery, Congressional Quarterly42(8): 453, 453–58 (February 25, 1984) (discussion of the resistance of the American Medical Association and the American Hospital Association to establishing federal standards for undertaking organ transplants).
3.
CaplanA.L., Organ Transplants: The Costs of Success, Hastings Center Report13(6): 23–32 (December 1983).
4.
In a story about the Baby Fae xenograft, it is reported that Charles McCarthy, Director of the Office for Protection from Research Risks at the National Institutes of Health, declined to review the informed consent and research protocol used at Loma Linda Medical Center. McCarthy stated: “It is not NIH policy to investigate research work performed without federal fundshellip; See BreoD.L., Interview with Baby Fae's Surgeon, American Medical News, November 16, 1984, at 16. Unless NIH policy is changed, or unless an individual institution's institutional review board chooses to engage in review, research conducted with private funds will not be subject to review by IRBs or, if it does not involve new drugs or devices, by the Food and Drug Administration or any other federal agency.
